hemagglutination occurred in less than 1% of sera; these sera were absorbed for 1 h with an equal volume of 20% glutaraldehyde-preserved SRBC in normal saline and retested.
Available tests for antibody to hepatitis B core antigen (anti-HBc) are complicated. A passive hemagglutination assay for anti-HBc was developed by sensitizing sheep erythrocytes with hepatitis B core antigen synthesized by a recombinant DNA technique. It was compared with a commercial passive hemagglutination assay and an enzyme-linked immunosorbent assay for anti-HBc and showed good agreement with both. It is rapid, simple, and sensitive.
Antibody (anti-HBc) to hepatitis B core antigen (HBcAg) is a useful marker for hepatitis B virus infections (4, 5) . The development of tests for anti-HBc has been hampered by the limited supply of HBcAg. Recently, an HBcAg synthesized by a recombinant DNA technique has been successfully used in a radioimmunoassay (3, 7, 9) and an enzyme-linked immunosorbent assay (8) Comparable results obtained with the two PHAs was due to the use of identical synthetic HBcAgs in both tests; however, small differences in results reflected differences in standardization. The control for nonspecific hemagglutination included only in our PHA optimized specificity. We found occasional false-positives with Corecell, owing to heterophile antibody, despite the presence of SRBC stroma in its diluent. An agreement of 98% between Corzyme and our PHA indicated that both tests were approximately equal in sensitivity and specificity, but the PHA is simpler, rapid, and inexpensive. When HBcAg is purchased, our PHA is 10 and 20 times less expensive than Corecell and Corzyme, respectively. In addition to describing a useful test, this study supported the findings of other studies (3, (7) (8) (9) that synthetic HBcAg is the antigen of choice for developing tests for anti-HBc.
Anti-HBc, used in conjunction with HBsAg and antiHBsAg, is very useful in the screening of candidates for receipt of hepatitis B virus vaccine (6; C. J. Oon, L. Chan, and R. Guan, Letter, Lancet i:1272, 1983). The benefit of screening blood donors for anti-HBc remains controversial (1, 2, 10) , but the PHA is highly applicable for this purpose. Our PHA can be used for immunoglobulin M anti-HBc by adding HBcAg-sensitized SRBC to immunoglobulin M antiHBc captured to U-bottom microtiter plates, thereby forming a sheet of SRBC on the bottom of the well; an evaluation of this procedure is in progress.
A simple, rapid, inexpensive, sensitive, and specific PHA for anti-HBc is highly applicable in developing countries where hepatitis B virus infections are hyperendemic.
P. Wingfield of Biogen S.A. and K. Murray of the University of Edinburgh donated HBcAg for this study. F. Deinhardt made the necessary correspondence leading to these donations.
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